Clinical Trials

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07513324 2026-04-07

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

116 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07509099 2026-04-03

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07486687 2026-03-20

PLANET

1,000 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Lymphoid

Hodgkin Disease

NCT07475572 2026-03-16

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

120 enrolled

Dermatologic

Melanoma

NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

111 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT07452224 2026-03-12

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07466927 2026-03-12

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

30 enrolled

HER2-negative Breast Cancer

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Carcinoma, Renal Cell

NCT07409844 2026-02-20

RESET C2

152 enrolled

Colonic Neoplasms

NCT05741164 2026-02-17

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

37 enrolled

Triple Negative Breast Neoplasms

NCT07412054 2026-02-17

BLP-HCC

234 enrolled

Carcinoma, Hepatocellular

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07360743 2026-02-10

META-1

275 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

8 enrolled

CNS

Turcot syndrome, Glioblastoma

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

718 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07346053 2026-01-16

Chrono-EVP

224 enrolled

Advanced Bladder Cancer

NCT07347210 2026-01-16

MATVAC-1

98 enrolled

CNS

Primary Glioblastoma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 2/3 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

720 enrolled

Squamous NSCLC

NCT06093425 2025-12-17

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

820 enrolled

Stomach Neoplasms

NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

116 enrolled

Advanced Hepatocellular Carcinoma (HCC)

NCT06724042 2025-12-10

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

159 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

450 enrolled

Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

28 enrolled

Gynecologic

Advanced Endometrial Cancer

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

160 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06400160 2025-11-25

Clinical Trial of TB511 in Advanced Solid Tumors

GastrointestinalGenitourinary

12 enrolled

Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms

NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

30 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07199413 2025-09-30

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

20 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

122 enrolled